Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Lilly Inks Development, Study Agreements

Tuesday, October 13, 2015 06:07 PM EDT Updated: Wednesday, October 14, 2015 09:13 AM EDT
Lilly Inks Development, Study Agreements (Image Courtesy: Lilly Oncology)

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has announced details of two partnerships. Innovent Biologics Inc. in China and Lilly have expanded an existing drug development relationship and a new research collaboration with California-based ImaginAb Inc. involves preclinical studies of potential immuno-oncology therapies.

Under the Innovent agreement, Lilly will "opt-in" for co-development and commercialization, while the Chinese company will develop, manufacture and commercialize the potential cancer treatments in China. The deal involves up to three antibodies over the next ten years. It also includes financial incentives if the potential drugs reach certain milestones. You can read additional details by clicking here.

Lilly Vice President of Oncology Research Greg Plowman "we believe that combination therapy in immuno-oncology has the potential to transform the way cancer is treated. We are pleased to be expanding our collaboration with Innovent to further the development of potential therapies for those fighting cancer in China and around the world."

Lilly and ImaginAb’s partnership will focus on potential T-cell-based immuno-oncology cancer therapies. The agreement calls for ImaginAb to conduct research using an immune imaging agent involving T-cells in response to Lilly oncology molecules. The California company will maintain full rights to its imaging agents.

Plowman says this collaboration "demonstrates Lilly’s commitment to advancing biomarker-driven cancer therapies. ImaginAb has developed a highly specific and novel approach for visualizing a patient’s immune response, and we are excited to explore applications of this technology as part of our immuno-oncology drug development efforts." You can connect to additional information on the agreement by clicking here.

Story Continues Below

Most Popular Stories

  • Iconic ‘Hoosiers’ trophy gets new permanent home

  • Deep frozen storage facility opens in Greenfield

  • Startup lands $30M in funding to commercialize cancer imaging agent

  • IndyGo CEO leaving after four years leading transit agency

  • Performance management plays a key role in employee engagement

  • New president for Toyota Indiana

Perspectives

Performance management plays a key role in employee engagement

Performance management plays a key role in employee engagement

Employee engagement is a catchall term that refers to the degree to which employees are committed to their work and their organization. We all know that engaged employees are more productive, more creative, and more likely to stay with their organization. So, how does performance management impact employee engagement?...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service